Senior Management

Alligator Bioscience is guided by a seasoned executive leadership team dedicated to advancing our CD40-targeted immuno-oncology pipeline. Our management, led by CEO Søren Bregenholt and CFO Johan Giléus, brings deep commercial and scientific expertise to drive strategic growth and development.

Søren Bregenholt

CEO

• Independent in relation to the Company and its management: No
• Independent in relation to major shareholders: Yes
• Holdings in Alligator: 1,578,705 shares and 736,729 warrants TO 14, 1,200,000 warrants in program TO 2023/2026 I and 900,000 warrants in program TO 2024/2027 I.
• Other current positions: Chairman of the board of A Bioscience Incentive AB, Atlas Therapeutics AB, Oblique Therapeutics Ab and Kripthonite Therapeutics Aps.

• Full profile

Johan Giléus

CFO

• Independent in relation to the Company and its management: No
• Independent in relation to major shareholders: Yes
• Holdings in Alligator: 750,000 shares (through company) and 350,000 warrants TO 14.
• Other current positions: Board member of A Bioscience Incentive AB and Atlas Therapeutics AB. Board member and CEO of Giléus Consulting AB and Giléus Invest AB.

• Full profile